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Abstract: A series of eight copper (II) complexes with 3-(4-chloro-3-nitrophenyl)thiourea were designed
and synthesized. The cytotoxic activity of all compounds was assessed in three human cancer cell lines
(SW480, SW620, PC3) and human normal keratinocytes (HaCaT). The complexes 1, 3, 5, 7 and 8 were
cytotoxic to the studied tumor cells in the low micromolar range, without affecting the normal cells.
The complexes 1, 3, 7 and 8 induced lactate dehydrogenase (LDH) release in all cancer cell lines,
but not in the HaCaT cells. They provoked early apoptosis in pathological cells, especially in SW480
and PC3 cells. The ability of compounds 1, 3, 7 and 8 to diminish interleukin-6 (IL-6) concentration
in a cell was established. For the first time, the influence of the most promising Cu (II) complexes on
intensities of detoxifying and reactive oxygen species (ROS) scavenging the enzymes of tumor cells
was studied. The cytotoxic effect of all copper (II) conjugates against standard and hospital bacterial
strains was also proved.
Keywords: copper (II) complexes; thiourea; cytotoxic activity; proteome analysis; antimicrobial activity
1. Introduction
Enzymes incorporate transition metal cofactors to perform a wide range of metabolic
reactions. Among metal cations, copper (II) ions play an essential function in the human
organism, being a structural component of several enzymatic proteins, such as ascorbate
oxidase, ceruloplasmin, amine oxidase, cytochrome C oxidase, nitrite reductase and super-
oxide dismutase Cu–Zn (SODC) [1,2]. Complexes of organic chelators with Cu (II) have
been receiving increased attention due to their potential biomedical applications, such as
cytotoxic or antibacterial activities. Within a group of acylthiourea ligands, those containing
electron-withdrawing chloro- and nitro-substituents were effective against adenocarcinoma
cell lines [3]. Intercalating properties of N-(2-hydroxyethyl)-N′-benzoylthiourea-Cu (II)
complexes with strong deoxyribonucleic acid (DNA) binding and cleavage abilities were
denoted [4]. Chelates with orthophenanthroline units studied by Pivetta et al. exerted high
cytotoxic affect against acute leukemia and other carcinomas [5]. Moreover, a wide an-
tibacterial profile of copper-based thiourea coordinates of 4-azatricyclo-3,5-dione [6] and
3-(trifluoromethyl)aniline was also studied. Their inhibitory effect on bacterial topoiso-
merases was also established [7].
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Requirements for safer, more active and more selective chemotherapeutics have stim-
ulated the search for other metal-based antitumor candidates. First of all, investigations
in the treatment of cancer diseases are oriented to synthesize new analogues of cisplatin,
a platinum (II) coordinate and chemotherapeutic drug effective against various types of
tumors. Recently published Pd (II) and Pt (II) complexes of N-allylthioureas containing
morpholine and tert-butylamine moieties showed proapoptotic and cytostatic influence on
HeLa (Henrietta Lacks) cell culture stronger or comparable with cisplatin [8]. Antitumor
properties of structurally similar coordinates based on pyrazol-3-ylpyridine fragments were
connected with their inducing effect on cell accumulations in the S phase (HeLa cells) and
a reduction of cell subpopulations in G2/M and G0/G1 phases (pancreatic cancer cells) [9].
Among tested palladium complexes of N, N-disubstituted thioureas, those endowed with
furoyl and ethyl groups were the most effective against human breast cancer cells, as com-
pared to the platinum-derived standard drug [10]. On the other hand, Marverti et al. [11]
introduced a series of thiourea-Pd (II) compounds that acted as productive growth in-
hibitors of cisplatin-sensitive ovarian cancer cell lines and their resistant counterparts.
Coordinates altered malignant cell metabolism via inhibition of thymidylate synthase
and dihydrofolate reductase expression. Interestingly, photoactivated platinum (IV) azide
dipyridine complexes bonded strongly to the nuclear DNA of tumor cells and blocked
ribonucleic acid (RNA) polymerase II more efficiently than conventional adducts of cis-
platin [12]. Platinum (II)-acridine hybrids linked to the amidine group [13] have shown
inhibition of lung cancer cell proliferation and a promising antitumor potency in mouse
xenograft models. In contrast, cationic gold (I) complexes of thiourea containing an acridine
core are devoid of cytotoxic properties. However, they exert remarkable activity against
M. tuberculosis [14]. Gold (I) complexes of cyclic disubstituted 4-chlorophenylthiourea
ligand severely affected mitochondrial respiration by inhibition of complexes II and IV of
the respiratory chain and induced mitochondrial swelling, resulting in enhanced perme-
ability of a membrane and its declined fluidity [15]. An alternative class of anticancer drugs
has been identified within ruthenium (II)–arene compounds. The Ru (II)-acylthiourea
organometallic complexes were found to be significantly cytotoxic towards lung [16–18],
prostate [16] and breast [18] tumor cell cultures, inducing their apoptosis and reducing
migration by interaction with human serum albumin. What is more, other results showed
that silver (I) chelates of 2-benzimidazolylurea mediate a strong cytotoxic response to the
tested breast cancer cell lines (MCF-7) and normal cells, but with better parameters than
metallodrug cisplatin [19].
Reactive oxygen species (ROS), produced in the mitochondria, peroxisomes and en-
doplasmic reticulum, include highly reactive species such as hydroxyl and superoxide
free radicals, singlet oxygen or less reactive hydrogen peroxide molecules. Regulation of
ROS levels is crucial for cellular life, cell proliferation and differentiation. Under oxida-
tive stress states, accumulation of ROS causes the damage of proteins, lipids and DNA,
which contributes to carcinogenesis [20]. The expanded scavenging system of a cell is based
on superoxide dismutases (SODs), glutathione peroxidase (GPX), glutathione reductase
(GR), peroxiredoxins (PRDXs), thioredoxin and catalase (CAT), which neutralize reactive
species or recover antioxidants to their reduced state [21]. In comparison with normal cells,
an extent of ROS in cancer counterparts is higher, as they keep an improved antioxidant
system [22]. What is more, expanded levels of GPX, CAT, glutathione and thioredoxin
proteins are correlated with tumor aggression and its resistance to chemotherapy [22].
It was proved that a decline of ROS-scavenging capacity leads to apoptosis of malignant
cells, especially when it is used in combination with ROS-increasing chemotherapeutics,
such as 5-fluorouracil (therapy of colon cancer), celecoxib (prostate tumor) or doxorubicin
(breast, liver cancers) [21,23–26]. Numerous organic complexes with transition metals are
reported to induce autophagy and/or apoptosis by regulation of ROS. This group includes
complexes of gold (I) with thiourea [15,27], ruthenium (II) coordinates with β-carboline [28],
copper (II) complexes with 2-hydroxy-1-naphthaldehyde [29] and with the derivative of
bipyridine-acetylacetonate (Casiopeina III-ia) [30]. The antioxidant abilities of coordi-
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nates evaluated by the diphenyl-2,2-picrylhydrazyl/ N, N-diethyl-p-phenylenediamine
(DPPH/DPD) method were also confirmed for ruthenium (III) chelates with 1-ethyl-3-
phenylthiourea ligands [31] and copper (II) complexes with biuret or urea [32], as well as
with auxin [33] or N-ethylpiperazine [34].
As a part of our research on developing biologically active 1,3-disubstituted thioureas [7,35–37],
we have synthesized a series of halogenated copper (II) complexes of (4-chloro-3-nitrophenyl)
thiourea and reported their cytotoxic, prooxidant and antimicrobial properties.
2. Results and Discussion
2.1. Synthesis of Complexes
Thiourea–Cu (II) coordination compounds 1–8 were prepared by the reaction of copper
(II) chloride with 3-(4-chloro-3-nitrophenyl)thiourea compounds (Figure 1). The complexes
were obtained with satisfactory yields (45–61%). The identification of the parent ligands
L1–L8, using nuclear magnetic resonance (NMR) and mass spectroscopy, was described
previously [37,38]. The derivatives chosen for complexation reactions came from a series
of mono- (L4–L6) or di-halogenated (L1–L3, L7, L8) 1-phenylthioureas with the most
promising bioactivity. The presented selection of the phenyl ring substituents in their
structures allow for the analysis of the influence of the substitution isomerism, as well
as the impact of electron-withdrawing elements on the biological properties of newly
synthesized metal–organic compounds.
Figure 1. Scheme of the complexation reaction of the respective arylthiourea ligands L1–L8 with proposed molecular
structures of complexes 1–8 (DMF—dimethylformamide).
2.2. Structural Characterization of Complexes
The complexes were initially characterized by elemental analysis and infrared spec-
troscopy. During all complexation reactions, disubstituted thiourea acts as bidentate ligand
(L), forming a hydrated complex of the type CuL2. In order to determine the geometry of
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metal–organic ligand complexes, ultraviolet–visible (UV–Vis) and electron paramagnetic
resonance (EPR) spectroscopies have been applied.
The infrared spectra of ligands (L1–L8) exhibit a broad band with several maxima
in the high-energy part (Figure 2), corresponding to the stretching vibrations of the N–H
and C–H groups. In the spectra of Cu (II) complexes (1–8), this band widens (Figure 2),
which confirms the presence of water molecules in the product of the complexation reac-
tions. The molecules of the initial ligands (L1–L8) and their complexes (1–8) contain two N–
H groups (Figure 1), which are reflected in two infrared absorption bands. These bands are
in different positions in the spectra of a pair of free and bonded ligands (Figure 2, Table 1).
This confirms deprotonation of one N-atom from the ligand’s molecules and suggests
different intermolecular interactions (N–H... X; X=O, Br, Cl, F, I hydrogen bonding patterns)
in the crystal structure of free and bonded thioureas. The region of 1600–1400 cm−1 in the
spectra of ligands (L1–L8) is dominated by the stretching vibrations of the C–C and C–N
bonds. In the spectra of complexes (1–8), this feature is extended towards the higher fre-
quencies (around 1700 cm−1, Figure 2) as the consequence of increased intensities of asym-
metric ring stretching modes within the molecules of complexes [7]. The spectral ranges:
1550–1500 cm−1 (NO2 asymmetric stretching vibrations), 1360–1330 cm−1 (NO2 symmetric
stretching vibrations) and 1240–1040 cm−1 (C–halogen stretching modes) are quite similar
for parent ligands and their Cu (II) complexes (Table 1), which excludes the interaction of
the nitro group or the halogen atom with the metal cation. The bands corresponding to
the C=S stretching vibrations are found around 1333 cm−1 and in the 854–832 cm−1 range
in the uncomplexed ligand’s spectra (Table 1). In the spectra of complexes, they are red
shifted and observed at 1313–1300 cm−1 and 785–771 cm−1 regions (Table 1). This indicates
that the ligands coordinate to the Cu (II) through the sulfur atom [39–41].
Figure 2. Attenuated total reflection infrared (ATR-IR) spectra of one exemplary pair of a free ligand
(L5) and a complex (5) in the range of 3600–900 cm–1. ATR-IR spectra of all studied compounds are
gathered in the Supplementary Materials (Figure S1).
The electronic spectra of the complexes (Figure 3) exhibit the intense absorption bands
in the region 230–300 nm corresponding to the π→π* and n→π* intra-ligand transitions.
The presence of S→Cu (II) ligand-to-metal charge transfer (LMCT band) around 400 nm
is additional evidence of the coordination of thiourea ligands to the metal cation via
sulfur atom [39,40,42]. All presented compounds show the d-d bands in a wide region
650–1400 nm, which confirms the formation of four-coordinate complexes with copper on
+2 oxidation state [41].
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Table 1. Characteristic infrared absorption bands of N−H, NO2, C=S and C−X (X = Br, Cl, F, I) groups. Band position in cm−1,
intensity: w is weak, m is medium, s is strong, vs is very strong, sh is shoulder, as is asymmetric, s is symmetric, * is broad band.
Compound υN−H υasNO2 υsNO2 υC=S υC−X
1 3470 w, 3372 m 1529 m * 1347 m * 1301 m, 782 w 1047 w
L1 3340 w, 3209 m 1537 sh, 1526 vs 1347 sh 1332 m, 832 m 1044 m
2 3444 w, 3395 w 1531 m * 1344 m * 1306 w, 776 w 1070 w
L2 3334 sh, 3250 m 1547 m, 1526 m 1352 m, 1333 s 1332 m, 834 w 1067 m
3 3448 w, 3333 w 1530 m * 1351 m * 1305 w, 774 sh 1071 w
L3 3361 w, 3317 s 1537 sh, 1525 s 1355 m * −, 839 w 1070 m
4 3449 w, 3335 m 1531vs * 1344 m * 1311 m, 781 w 1051 m
L4 3365 sh, 3244 s 1546 m, 1525 s 1353 m, 1335 s 1335 m, 840 m 1049 m
5 3449 w, 3333 m 1529 vs * 1344 m * 1300 m, 779 sh 1050 m
L5 3348 sh, 3243 s 1539 vs, 1509 sh 1347 sh, 1331 s 1331 m, 835 m 1050 m
6 3449 w, 3340 m 1539 sh, 1519 vs 1341 m * 1313 m, 784 w 1044 m
L6 3327 s, 3243 m 1542 m, 1515 s 1353 w, 1333 m 1333 m, 837 sh 1047 m
7 3446 w, 3341 m 1532 m * 1346 m * 1313 m, 785 w 1236 w
L7 3325 s, 3242 m 1539 s, 1518 vs 1356 s, 1335 s 1335 m, 854 w 1232 w
8 3448 w, 3336 w 1532 m * 1350 m * 1307 w, 771 w 1057 w
L8 3364 s, 3314 m 1538 s, 1525 s 1350 s * 1331 sh, 833 sh 1059 m
Figure 3. Solid state ultraviolet–visible (UV–Vis) spectra of complexes in the range of 220–1400 nm.
EPR spectra of the investigated complexes 1–8 (Figure 4) are in agreement with the
conjectures drawn based on the infrared (IR) and UV–Vis results. The obtained spectra
indicate clearly the divalent state of copper upon complexation and are very characteristic
of typical Cu (II) complexes. The signals were simulated assuming rhombic symmetry with
the z component (parallel) split into four lines due to the hyperfine interaction between the
unpaired electron and nuclear magnetic moment of copper (I = 3/2, 63,65Cu). The splitting
of the perpendicular line (x and y components) remains unresolved, yet it was necessary
for obtaining the correct shape of the simulated spectra. Slight rhombicity of the spectra
with gzz >> gxx > gyy confirms dominant contribution of a single d-orbital (3dx2–y2) in
the semi-occupied molecular orbital. Exemplary parameters obtained for compound 5
are: gxx = 2.086, gyy = 2.054, gzz = 2.357, Axx and Ayy unresolved, |Azz| = 12.8 mT.
Similar parameters were recently reported for Cu (II) thiourea complexes [6,7]. The EPR
parameters obtained for other complexes are very similar (12.6 mT < |Azz| < 12.8 mT,
2.353 < gzz < 2.358), which strongly indicates very similar coordination around the copper
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center. It is in agreement with the molecular structure of the complexes (with two thiourea
ligands chelated to the Cu (II) cation via deprotonated N and thiocarbonyl S atoms),
which differ only in the substituents of thiourea ligands (Figure 1). Such modification
has only a minute effect on the first coordination sphere of copper, to which continuous
wave EPR is sensitive. No features characteristic of Cu dimer in solution were observed,
e.g., a forbidden magnetic dipolar transition at half-field with g = 4 value.
Figure 4. Frozen solution (77 K) X-band electron paramagnetic resonance (EPR) spectra of complexes
1–8, along with exemplary computer simulation of spectrum for the complex 5.
The molecular structure proposed for compounds 1–8, in which the Cu (II) cation is
the part of two four-membered rings (Cu-S-C-N, see Figure 1), is quite unusual for copper.
However, this type of coordination was reported for one crystal structure determined
by Singh et al. [43]. They found Cu (II) ions being chelated by two thiourea ligands in a
trans manner and the distorted square-planar geometry of the complex was stabilized by
electron delocalization in chelate rings. Moreover, such coordination was postulated by
some of the authors of the current study for another series of Cu (II) complexes, namely
for 3-(trifluoromethyl)phenylthiourea derivatives [7] and thioureas containing tricyclic
imide’s part [6,41]. Structural characterization of those complexes, possibly owing to the
combination of several experimental laboratory and synchrotron techniques (including
X-ray absorption spectroscopy) and molecular modelling, indicated that 1,3-disubstituted
thiourea ligands coordinate to Cu (II) cation in bidentate fashion through S and N atoms,




In vitro cytotoxicity studies of synthesized thiourea complexes 1–8 were assessed by
standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) bioassay in
different cancer cells at 72 h of drug exposure (Table 2). The ability of compounds to inhibit
cell proliferation was established by means of their half-maximal inhibitory concentration
(IC50) values towards the human tumor cell lines, such as SW480 (primary colon cancer),
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SW620 (metastatic colon cancer) and PC3 (metastatic prostate cancer), as well as against
the non-tumor cell line HaCaT (immortal keratinocytes).
Table 2. Cytotoxic activity (IC50, µM) of studied compounds estimated by the MTT assay a.
Compound Cancer Cells Normal Cells
SW480 d SW620 e PC3 f HaCaT g
R IC50 b SI c IC50 SI IC50 SI IC50
1 2-Br-Ph 4.7 ± 0.3 23.2 3.3 ± 0.2 33.2 9.7 ± 0.1 11.5 109.6 ± 3.4
2 3-Br-Ph 24.3 ± 2.6 6.8 22.3 ± 1.8 7.5 19.2 ± 2.2 8.7 167.2 ± 2.3
3 4-Br-Ph 11.9 ± 2.1 8.6 19.2 ± 2.3 5.3 8.8 ± 0.8 11.7 103.2 ± 3.2
4 3-Cl,4-F-Ph 19.2 ± 1.1 6.3 21.6 ± 2.9 5.7 23.2 ± 1.6 5.2 120.9 ± 5.2
5 3-Cl,4-Cl-Ph 20.6 ± 2.1 8.1 10.8 ± 2.6 15.2 11.4 ± 2.4 14.4 164.9 ± 4.7
6 3-NO2,4-Cl-Ph 26.8 ± 2.3 4.6 21.5 ± 1.4 5.7 20.3 ± 3.1 6.1 123.2 ± 2.1
7 2-F-Ph 15.5 ± 2.6 8.9 9.1 ± 0.8 12.8 10.8 ± 1.3 5.5 138.3 ± 4.4
8 4-I-Ph 3.9 ± 0.8 26.3 17.8 ± 1.3 5.7 4.3 ± 0.5 23.8 102.7 ± 3.4
Doxorubicin h 0.75 ± 0.1 0.4 0.26 ± 0.1 1.1 0.31 ± 0.1 0.9 0.29 ± 0.1
Cisplatin i 10.4 ± 0.9 0.6 6.7 ± 1.1 0.9 13.2 ± 2.1 0.5 6.3 ± 0.7
CuCl2 j 109.4 ± 7.6 1.0 96.3 ± 5.2 1.2 106.5 ± 6.3 1.1 114.3 ± 4.8
a MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. Data are expressed as mean standard deviation (SD);
b IC50 (half-maximal inhibitory concentration, µM): the concentration of the compound that corresponds to a 50% growth inhibition
of the cell line (as compared to the control) after culturing the cells for 72 h with the individual compound; c the SI (selectivity index) was
calculated using the formula SI = IC50 for normal cell line/IC50 cancer cell line; d human primary colon cancer (SW480); e human metastatic
colon cancer (SW620); f human metastatic prostate cancer (PC3); g human immortal keratinocyte cell line from adult human skin (HaCaT);
h,i,j the reference compounds.
The 1,3-disubstituted arylthiourea complexes 1, 3, 5, 7 and 8 were cytotoxic to studied
cancer cells at concentration ≤ 10 µM. The monohalogen derivatives 1 and 8 showed cyto-
toxic activity in the low micromolar range in all tested pathological cell lines. Their IC50 values
ranged from 3.3 ± 0.2 to 9.7± 0.1 µM (compound 1) and between 3.9± 0.8 and 17.8± 1.3 µM
for compound 8. In particular, they both were strongly potent towards SW480 cells (at
3.9 ± 0.8 and 4.7 ± 0.3 µM), whereas derivative 1 was against SW620 (at 3.3 ± 0.2 µM) and
derivative 8 towards the PC3 cell line (with IC50 of 4.3 ± 0.5 µM).
The 4-bromophenyl compound (3) exerted remarkable growth-inhibiting activity
mainly against PC3 cells (8.8 ± 0.8 µM). On the other hand, the 2-fluorophenyl-containing
molecule 7 exerted the highest IC50 values for SW480 and PC3 cell lines (9.1 ± 0.8 and
10.8 ± 1.3 µM, respectively). Dichlorophenyl derivative 5 was potent against SW620 cancer
cells at 10.8 ± 2.6 µM.
In general, the PC3 cell line was the most sensitive to the presence of new com-
plexes, and substances 1, 3 and 8 appeared the most effective in the inhibition of their rise.
The same set of compounds acted the strongest against primary cancerous SW480 cells.
In contrast, for substances 1, 5 and 7, the lowest IC50 indexes for metastatic SW620 cells
were denoted. The cytotoxicity of other tested derivatives (2, 4, 6) towards pathological
cell lines was moderate, with IC50 values from 19.2 ± 1.1 to 26.8 ± 2.3 µM.
The studied thiourea complexes were non-cytotoxic against normal HaCaT cell lines
(IC50 > 100 µM). The highest selectivity indexes (SI) were observed for the most promising
derivatives: 1 (33.2 vs. SW620; 23.3 for SW480) and 8 (26.3 vs. SW480; 23.8 vs. PC3 cells).
The selectivity factors of other complexes 2–7 were in the range of 4.6–8.9 (SW480),
5.3–15.2 (SW620) and 5.2–14.4 (PC3 cell line). These indexes were incomparably greater
than those of the reference doxorubicin and cisplatin (SI between 0.4 and 1.1), which proves
a low toxicity of tested complexes towards health cells.
As compared to cisplatin, the cytotoxic properties of the synthesized diarylthiourea
derivatives were considerably stronger. Complexes 1, 3, 5, 7 and 8 were 1.2–3.1-fold more
active against human PC3 cell lines. Additionally, both studied colon cancer cell lines
appeared to be 2–2.7 times more sensitive to the presence of coordination compounds 1
and 8 than cisplatin, one of the most frequently used chemotherapy drugs.
The present study reveals that monohalogen substituted phenylthiourea complexes (1–3, 7, 8)
possess stronger cytotoxic properties in human cancer cell lines, when compared to disub-
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stituted derivatives (4–6). The moderately electronegative atom, such as bromine or iodide
at the ortho (1,7) or para (3, 8) position of the aromatic ring, was responsible for enhanced
cytotoxicity in the MTT model. The location of an element at meta position (2) resulted in
a severalfold reduction in anticancer activity. Among disubstituted halogen coordinates,
the 3,4-dichlorophenyl derivative (5) appeared to be the most effective towards SW620 and
PC3 cells. The substitution of the benzene with chlorine and nitro group together provided
a less promising drug candidate (6), with IC50 at least 20.3± 3.1 µM against all tested cancer
cells. Comparing pairs 7 (2-fluorophenyl-) and 4 (4-fluoro-3-chlorophenylthiourea), an in-
troduction of the second halogen to the molecule led to the twofold decrease in cytotoxic
activity vs. metastatic SW620 and PC3 cell lines. In fact, the location of two different groups
in both third and fourth position of the ring was not beneficial on biological activity (4,6).
Only 3,4-dichlorophenyl complex (5) restrained the potency in the low micromolar range,
as compared to its monohalogen analogs 3 and 7. To sum up, the phenyl ring sub-
stituents can be arranged in order of their decreasing impact on bioactivity as follows:
2-bromo > 4-iodo > 2-fluoro > 4-bromo > 3,4-dichloro >> 3-chloro-4-fluoro > 3-bromo > 3-nitro-4-chloro.
It is worth noting that all of them were at least 350 times less toxic for normal HaCaT
cell lines than reference doxorubicin.
As reported, the cytotoxicity of standard copper (II) chloride towards cancer cells
was negligible in comparison with thiourea derivatives. Its C50 ranged between 96.3 and
109.4 µM, and the salt was nontoxic for normal cells (IC50 >100 µM). DMF, an organic
solvent that contaminates synthesized complexes, has already been tested on various
cells and appears to be nontoxic at the concentrations used in our synthesis (see in the
Supplementary Material section). Considering an influence of starting ligands L1–L8 on
studied cell lines, the derivative L5, at the concentration 8 µM, caused an approximately 20%
decrease in HaCaT cell viability, which indicated its weak cytotoxic impact against normal
cells [36]. In contrast, new complexes are devoid of visible influence on keratinocytes.
In preliminary tests published previously, ligands L1, L3–L5 and L8 influenced the growth
of other cancer cells, such as human leukemia and solid (melanoma, prostate) tumors,
as well as normal tissue foreskin fibroblasts [36]. These results encouraged us to proceed
with deeper investigations on the cytotoxicity mechanism of complexes 1–8.
LDH Assay
The lactate dehydrogenase (LDH) release assay was used to determine the level of
plasma membrane damage of the most distinctive derivatives 1, 3, 7, 8. They were studied
at concentrations of 10–60 µM against cancer cell lines and 60–120 µM towards normal
HaCaT cells.
The LDH release curve results (Figure 5) demonstrated that the applied amounts of
complexes did not affect the normal keratinocytes viability, as the secretion of LDH in
their presence varied from 1.3% to 5.7%. The 4-iodophenylthiourea complex 8 exerted
the highest cytotoxicity against all three tumor cell lines. This effect was the most evident
in PC3 and SW480 cells, compared to SW620. When used at 60 µM, the derivative 8
achieved 64% LDH release in PC3 cells and 58% in SW480 cell lines. LDH secretion in
these cells accounted for other complexes, used at the highest concentrations, ranging
from 19% to 32%. The compound 8, applied in a dose of 40 and 20 µM, also expressed an
increased response against SW480 cells (LDH release was 46.4% and 42%, respectively).
Similarly, the LDH leakage induced in PC3 cells by this derivative used at lower concen-
trations differed from 56.4% (40 µM) to 27.2 % (10 µM). On the other hand, the number
of lysed SW620 cells evoked by the presence of the 2-bromophenylthiourea complex 1
ranged from 48% (at 60 µM) to 22% (10 µM applied), and incubation of these cell lines
with the derivative 8 expressed similar enzyme releases of 42.4% and 23%, respectively.
2-fluorophenyl compound 7, studied at its highest dose, was less cytotoxic and achieved
30.2% LDH secretion.
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Figure 5. Lactate dehydrogenase (LDH) release as a marker of cell death in the SW480, SW620, PC3 and HaCaT cells, treated for 72 h with different concentrations of compounds 1, 3, 7 and 8.
LDH release in the HaCaT was analyzed after treatment with higher doses of compounds. *** p ≤ 0.001 as compared to the control.
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The reference cancer chemotherapeutic doxorubicin showed very high LDH release in
all studied cancer cell lines, even when applied in lower doses. The LDH percentage for
this compound at 1.5 µM varied from 70% to 98%. However, its toxicity against normal
HaCaT cells was significantly higher than examined complexes and accounted for 80%.
The data gained by the LDH activity assay are in an agreement with the results
obtained for derivatives 1, 3, 7 and 8 by the MTT method.
Apoptotic Activity
To establish the anticancer mechanism of activity, SW480, SW620 and PC3 cells were
incubated for 72 h in the presence of the most promising monohalogeno complexes 1, 3, 7 and 8,
after which annexin content was measured by flow cytometry analysis. The apoptotic
effect is shown in Figure 6 and Figure S2.
All studied compounds, applied in their IC50 doses, induced early apoptosis in
pathological cells, especially in SW480 and PC3 cell lines, as compared to untreated
cancerous controls. Derivatives of 2-bromophenyl- (1) and 4-iodophenylthiourea (8) re-
vealed the most significant early-apoptosis-activating effect in primary colon cancer cell
lines (45.18% ± 3.9% and 48.9% ± 3.4%, respectively). The influence of complexes bearing
4-bromophenyl (3) and 2-fluorophenyl (7) moieties in these cells was not so evident and
did not exceed 40%. The most potent activators of apoptosis in metastatic PC3 cells were
both para-substituted coordination compounds 3 and 8, as they promoted the process
in 45.5% ± 3.5% and 45.7% ± 3.3% of cells. On the other hand, complexes containing a
halogen atom in ortho position of the benzene ring (1 and 7) induced the early apoptosis in
one third of tested PC3 cells. The similar pro-apoptotic inducing effect of these two com-
pounds was observed in metastatic colon cancer cells (38.4% ± 2.4% and 35.4% ± 2.8%).
The incubation of these cells with derivatives 3 or 8 increased early apoptosis in only
approximately 20%.
The studied set of thiourea complexes did not considerably promote the process of late
apoptosis of cells, as compared to controls. Only the most cytotoxic derivative 8 had the late
apoptosis activating property, in 20.7% ± 2.8% of SW480 cells. It is also worth noting that
tested coordination compounds 1, 3, 7 and 8 did not affect the level of early/late apoptosis
in normal human keratinocytes (HaCaT), giving the result from 1.6% to 9.2% only.
In addition, conducted studies revealed that the referential doxorubicin was only a
necrosis inducer. The number of SW480, SW620 and PC3 cells at the necrotic stage was
86%, 51% and 50%, respectively. Only in the case of PC3 cells, it induced late apoptosis
as well (23%). HaCaT cells were considerably sensitive to doxorubicin, which produced a
necrotic stage in 42% of cells, without affecting early and late apoptosis.
The obtained data comply with IC50 results found for mentioned cancer cells, partic-
ularly indicating the pro-apoptotic promoting role of complexes 1 and 8 in SW480 cells,
as well as substances 3 and 8 in the prostate cancer cell line.
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Figure 6. The effect of complexes 1, 3, 7 and 8 on early and late apoptosis, or necrosis in SW480, SW620, PC3 and HaCaT cells. Cells were incubated for 72 h with tested compounds used
in their IC50 concentrations. Then, cells were harvested, stained with annexin V-FITC and PI (fluorescein isothiocyanate and propidium iodide) and analyzed using flow cytometry.
*** p ≤ 0.001, ** p ≤ 0.01 as compared to the control.
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IL-6 Assay
Human interleukin-6 (IL-6) is a pro-inflammatory cytokine, involved in numerous
biological processes such as inflammation, cell growth, apoptosis, aging or bone remodeling.
The ability of compounds to diminish IL-6 concentration in a cell, as a measure of their
anti-inflammatory properties, was established for the most cytotoxic copper (II) complexes
of thiourea derivatives (1, 3, 7, 8).
As shown in Figure 7, tested derivatives applied in their IC50 doses inhibited inter-
leukin release in all evaluated cancer cell lines. Among them, the SW480 line was the
most susceptible for the inhibition of the IL-6 secretion, elicited by the presence of eval-
uated substances. The 4-iodophenyl-containing complex (8) diminished the IL-6 level
in these cells twofold. Similarly, the treatment of the primary colon cancer cells with
2-bromophenylyhiourea coordinate (1) reduced the cytokine amount 1.9 times. However,
the other complexes (3 and 7) decreased that level not more than by 30%, as compared
to the controls. The effectiveness of the complex 1 in metastatic SW620 cells equaled to
the referential doxorubicin. Both substances inhibited the concentration of IL-6 2.4 times,
while other tested derivatives diminished its secretion by an average of 23%. The strongest
effect in PC3 cells was denoted for the 4-iodophenylthiourea complex (8), which, just as
doxorubicin, diminished the IL-6 secretion almost twofold. On the other hand, the incuba-
tion of PC3 cells with the 2-bromophenyl compound (1) lowered the IL-6 concentration
1.5 times, with weaker effect of other complexes (3 and 7).
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Figure 7. Effects of thiourea complexes 1, 3, 7 and 8 on IL-6 levels, measured by enzyme-linked immunosorbent assay (ELISA) test. Data are expressed as the mean ± SD from three
independent experiments performed in triplicate. *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05, as compared to the control. DX (doxorubicin) is the reference compound.
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Proteomic Analysis of Antioxidant and Detoxifying Enzymes
To evaluate the impact of the tested compounds on antioxidant status, they were
screened for their influence on intensities of selected detoxifying and ROS-scavenging
enzymes, occurring in human cancer cell lines such as glutathione S-transferase (GST),
glutathione reductase (GR), superoxide dismutase (SOD) and peroxiredoxin (PRDX)
(Table 3 and Table S1).
All tested complex compounds, applied in their IC50 concentrations, reduced inten-
sities of colon and prostate cancer enzymatic proteins, in most cases by at least 30% of a
control. The types of studied thiourea terminal moieties can be arranged in order of their de-
creasing influence, as shown: 2-fluoro- (7), 4-bromo- (3), 4-iodo- (8) and 2-bromophenyl (1).
The most susceptible for the presence of tested coordinates were the proteins of metastatic
PC3 cells. The level of all tested enzymes in the PC3 cell was diminished, while simultane-
ously superoxide dismutase [Cu-Zn] (SODC), mitochondrial superoxide dismutase (Mn)
(SODM) and the majority of PRDXs belonged to the most sensitive. The 2-fluorophenyl
derivative (7) reduced the intensity of 12 prostatic enzymes by 20.8-87.6%. Among them,
both types of SOD and mitochondrial PRDX3 were the most vulnerable; their intensities
were reduced by at least 75%. The compound 3 diminished the amount of all tested pro-
teins in the PC3 cells by 29.4–69.1%, affecting most significantly the levels of both SODs.
Similarly, after treatment of the cells with the complex 8, the amount of 12 enzymes was
reduced by 31.5–75.2%, including glutathione S-transferase A1 (GSTA1), SODs, PRDX3
and PRDX4, which intensities equaled about 30% of a control. After incubation with the
coordinate 1, quantities of SODM and PRDX5 were diminished up to 29% of the initial level.
On the other hand, GSTA1, glutathione S-transferase P (GSTP1) and PRDX3 of
metastatic SW620 cells were the most susceptible to the treatment with copper (II) com-
plexes. The derivative 7 appeared to be the most powerful. It reduced intensities of all tested
colon proteins by 32.5–63.9%, most heavily both GSTs (up to 63.6%) and SODs (55.3%).
Other analogs (1, 3, 8) affected considerably mainly on GSTA1, leading to a 45.7% (compound 8)
and 54.8% (complex 3) decrease in the amount of this protein, respectively.
The impact of the tested compounds on enzymes of the primary SW480 cells was also
evident, but weaker than that observed for both metastatic lines. The quantitative changes
affected mainly GSTA1, SODC and PRDX4. The derivative 7 exerted the strongest effect,
reducing their intensities by 54.9%, 59.4% and 41.7%, respectively. Additionally, it dimin-
ished the amount of five other proteins by 28.4% or more. Complexes 1 and 3 acted simi-
larly to their analogs, but they also affected smaller group of enzymes, most significantly
mitochondrial glutathione reductase (GSHR) (compound 1) and PRDX4 (compound 3).
The thiourea coordination compound 8 had the greatest relevance for GSTA1, giving 47.6%
inhibition of its intensity.
Obtained results confirmed the cytotoxic effect of tested complexes by the decreasing
of antioxidant influence on cytoplasmic and mitochondrial proteins of malignant cells,
especially observed for derivatives 7 and 3.
According to the literature data, there are few evidences that suggest GSTs function
in the cancer development and resistance of colon and prostate tumor cells to anticancer
agents. Colon cancers reflected elevated levels of GST expression compared with normal
mucosa [44]. It was observed that GST overexpression was related to a doxorubicin-
resistance phenomenon [45]. Similarly, the high level of glutathione-S-transferase pi (GST-
pi) was detected in prostate cancer cells, and it contributed to the development of drug
resistance and a significant increase in the cell proliferation rate of androgen independent
PC3 cells [46].
Likewise, an increased GR expression and activity was shown in colon tumors,
where it was involved in cellular defense against ROS by producing a reduced form of
GSH. This activity may favor tumor development [47]. It was also shown that this enzyme
may protect PC3 cells under persistent ROS production induced by radiotherapy and
chemotherapy. Therefore, GR activity depletion could lead to the intensified H2O2 toxicity
in metastatic prostate cancer cells [48].
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There are contradictory reports indicating the function of SOD enzymes on primary
tumor proliferation and metastasis activity. It was shown that overexpression of SOD
could increase cell differentiation, decrease proliferation and turn back a malignant phe-
notype [49]. Other studies demonstrated that high SOD expression correlates with colon
tumor aggressiveness and with resistance to cytotoxic drugs and radiotherapy [50]. The loss
of SOD1 expression by siRNA knockdown significantly increased prostate cell sensitivity
to cytotoxic agents, confirming SOD1 participation in cellular response and resistance [51].
Some evidence has indicated SOD1 overexpression in cancers maintaining cellular ROS
below the crucial threshold [52]. Suddenly, down-regulation of SOD2 itself was reported in
breast cancer cell lines [53].
Table 3. Liquid chromatography–mass spectrometry (LC–MS) proteome analysis provided in the SW480, SW620 and PC3 cells treated
for 24 h with IC50 concentrations of complexes 1, 3, 7 and 8. Protein intensities were expressed as percentage of a control.
Protein Intensity, %
Accession Name of Enzyme
SW480 SW620 PC3
Control 1 3 7 8 Control 1 3 7 8 Control 1 3 7 8
GSTA1_HUMAN
Glutathione S-transferase A1 OS = Homo
sapiens OX = 9606 GN = GSTA1 PE = 1
SV = 3
100 78.3 86.6 75.6 91.6 100 50.2 45.2 36.4 54.3 100 84.4 70.6 79.2 73.5
GSTO1_HUMAN
Glutathione S-transferase omega-1
OS = Homo sapiens OX = 9606
GN = GSTO1 PE = 1 SV = 2
100 70.9 66.0 45.1 52.4 100 85.5 77.0 52.5 65.0 100 65.0 64.0 68.6 31.6
GSTP1_HUMAN
Glutathione S-transferase P
OS = Homo sapiens OX = 9606
GN = GSTP1 PE = 1 SV = 2
100 84.8 75.9 80.9 83.0 100 74.4 64.5 67.3 57.5 100 95.0 51.1 35.8 64.1
GSHR_HUMAN
Glutathione reductase, mitochondrial
OS = Homo sapiens OX = 9606
GN = GSR PE = 1 SV = 2
100 58.1 63.1 91.7 74.3 100 69.1 79.2 67.3 79.3 100 71.1 58.9 61.2 68.5
SODC_HUMAN
Superoxide dismutase [Cu-Zn]
OS = Homo sapiens OX = 9606
GN = SOD1 PE = 1 SV = 2




OS = Homo sapiens OX = 9606
GN = SOD2 PE = 1 SV = 3
100 67.8 77.7 65.1 94.3 100 88.8 77.1 45.3 92.7 100 29.1 31.2 25.2 29.4
PRDX1_HUMAN
Peroxiredoxin-1
OS = Homo sapiens OX = 9606
GN = PRDX1 PE = 1 SV = 1
100 95.9 88.5 71.6 84.4 100 96.1 89.0 83.2 93.5 100 73.9 47.8 46.5 52.3
PRDX2_HUMAN Peroxiredoxin-2 OS = Homo sapiens OX= 9606 GN = PRDX2 PE = 1 SV = 5 100 95.5 93.7 69.4 78.3 100 92.1 71.6 58.6 88.6 100 42.3 47.3 32.2 39.9
PRDX4_HUMAN
Peroxiredoxin-4
OS = Homo sapiens OX = 9606
GN = PRDX4 PE = 1 SV = 1
100 67.6 60.1 58.3 78.2 100 79.4 76.4 73.0 93.9 100 72.6 61.1 35.7 30.8
PRDX5_HUMAN
Peroxiredoxin-5, mitochondrial
OS = Homo sapiens OX = 9606
GN = PRDX5 PE = 1 SV = 4
100 77.3 84.8 91.0 81.7 100 88.3 82.4 81.4 74.4 100 29.3 40.9 36.7 42.0
PRDX6_HUMAN
Peroxiredoxin-6
OS = Homo sapiens OX = 9606
GN = PRDX6 PE = 1 SV = 3




OS = Homo sapiens OX = 9606
GN = PRDX3 PE = 1 SV = 3
100 95.2 85.4 90.4 96.3 100 69.9 67.5 61.2 95.2 100 69.5 57.3 12.4 24.8
Beyond the PRDX family protein’s regulatory function on cytokine-induced hydro-
gen peroxide concentration, some members can act independently during their perox-
idase activity on cell proliferation, differentiation, apoptosis and gene expression [54].
Recent studies highlight dual catalytic activities of PRDX1, because besides antioxidant
activity it has a physiologically significant overoxidation site [55,56]. The positive PRDXI
immunohistochemical staining was strongly associated with a poor response to neoadju-
vant chemoradiotherapy and a worse prognosis in rectal cancer patients [57]. The PRDX3
protein in antiandrogen resistant prostate cancer cell lines is responsible for increased
tolerance to oxidative stress and a lack of activation of pro-apoptotic pathways. Therefore,
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the knockdown of PRDX3 leads to an increased tendency to oxidative stress [58]. In vivo
studies showed the up-regulation of both PRDX3 and PRDX4 in prostate tumors. It could
be an attempt at adaptation of the cancer cells to the microenvironment in a way favorable
for survival and proliferation rate, while maintaining their tumor’s aggressiveness [59]
2.3.2. In Vitro Antimicrobial Activity
To assess the antimicrobial profile of coordination compounds 1–8, we assembled a
panel of isolates, which included Gram-positive and Gram-negative organisms of clinical
importance, as well as strains of fungal pathogens. The synthesized derivatives displayed
significant to weak inhibitory effects towards standard staphylococci, as shown in Table 4.
Derivatives of 3-chloro-4-fluorophenyl- (4) and 4-iodophenylthiourea (8) appeared to be
the most active, with MIC values of 4 µg/mL. Bromophenyl compounds (1 and 3) and
3-nitro-4-chlorophenyl-containing complex (6) moderately inhibited the growth of S. aureus
isolates, at concentrations from 4 to 8 µg/mL. The least potent monohalogen derivatives 2, 7
and dichlorophenyl complex 5 in doses of 16–32 µg/mL suppress the rise of staphylococcal
rods. On the other hand, Gram-negative strains were weakly susceptible to the presence
of tested thiourea coordinates (minimal inhibitory concentration, MIC ≥ 128 µg/mL).
No evident antifungal properties were also observed; compounds 2, 3, 6 and 8, applied only
at a dose of 64 µg/mL, exerted growth inhibitory properties towards studied Candida species
Table 4. In vitro activity of complexes 1–8 against standard bacterial and fungal strains—minimal inhibitory concentrations (MIC, µg/mL).
Strain 1 2 3 4 5 6 7 8 Ref. * Ref. **
S. aureus NCTC 4163 8 16 8 4 32 8 32 4 0.25 -
S. aureus ATCC 25923 8 16 8 4 32 8 32 4 0.5 -
S. aureus ATCC 6538 8 16 8 4 32 8 32 4 0.25 -
S. aureus ATCC 29213 8 16 16 4 32 8 32 4 0.25 -
S. epidermidis ATCC 12228 16 16 16 4 32 8 32 8 0.25 -
S. epidermidis ATCC 35984 8 16 16 4 32 8 32 4 ≤0.125 -
E. coli NCTC 10538 128 128 128 128 128 128 128 128 ≤0.125 -
E. coli ATCC 25922 256 128 >256 128 128 128 256 128 ≤0.125 -
P. aeruginosa ATCC 15442 128 128 128 128 128 128 >256 128 0.5 -
P. aeruginosa ATCC 27853 128 128 128 128 128 128 128 128 0.5 -
C. albicans ATCC 10231 ≥256 64 64 128 128 64 128 64 - 0.5
C. albicans ATCC 90028 ≥256 64 64 128 128 64 128 128 - 0.5
C. parapsilosis ATCC 22019 ≥256 64 64 64 64 64 128 64 - 0.5
Ref. *—Ciprofloxacin, Ref. **—Fluconazole.
On extended testing, a series of copper (II) complexes showed activity against 30 clinical
methicillin-resistant strains of S. aureus (MRSA) and S. epidermidis (MRSE) (Table 5), and their
potency against most of above-mentioned cocci was severalfold higher than the reference
ciprofloxacin. The derivative 3, possessing 4-bromophenyl substituent at the thiourea
branch, exhibited its growth-inhibitory effect towards all evaluated hospital S. aureus
rods with MIC of 4 µg/mL, whereas against most of S. epidermidis species at a dose
of 4–8 µg/mL. The similar sensitivity of clinical isolates of S. aureus to the presence of
3-chloro-4-fluorophenyl complex (4) was observed. Monosubstituted compounds, contain-
ing bromine (1, 2), fluorine (7) and iodide (8) on the phenyl ring, also possessed a moderate
antibacterial potency (MIC 4–8 µg/mL). However, complexes 3, 4, 7 and 8 were 64 times
more active towards S. aureus 572 and 481 strains than ciprofloxacin, while the bioactivity
of coordinates 1–4, 7 and 8 against six clinical S. aureus rods was 16–64 times stronger than
the reference drug. Disubstituted derivatives 5 and 6 acted with lesser strength than their
analogues incorporating one halogen in a molecule, but they were still 4–16 times more
potent as compared to ciprofloxacin.
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Table 5. In vitro activity of complexes 1–8 against hospital methicillin-resistant strains of Staphylococcus aureus (MRSA) and
Staphylococcus epidermidis (MRSE)—minimal inhibitory concentrations (MIC, µg/mL).
Strain 1 2 3 4 5 6 7 8 Ref. *
S. aureus 498 8 8 4 4 16 32 4 8 0.5
S. aureus 537 8 8 4 4 16 32 8 8 256
S. aureus 567 8 8 4 4 16 32 4 8 0.5
S. aureus 568 8 8 4 4 16 32 8 8 0.5
S. aureus 573 8 8 4 4 16 32 8 8 128
S. aureus 585 8 8 4 4 16 32 8 8 256
S. aureus 586 4 8 4 4 16 32 8 8 0.5
S. aureus 495 8 8 4 4 16 32 8 4 0.5
S. aureus 496 8 8 4 8 32 32 8 8 0.25
S. aureus 497 8 8 4 8 16 32 8 8 256
S. aureus 514 8 8 4 4 32 32 8 4 128
S. aureus 522 8 8 4 4 16 32 8 4 256
S. aureus 572 8 8 4 4 16 32 4 4 256
S. aureus 481 8 8 4 4 16 32 4 4 256
S. epidermidis 420 4 8 8 4 32 64 8 8 0.5
S. epidermidis 423 8 8 4 4 32 64 8 8 0.5
S. epidermidis 424 8 8 4 8 32 64 8 8 16
S. epidermidis 469 8 8 4 4 32 64 8 8 0.5
S. epidermidis 471 8 8 8 8 32 64 8 8 32
S. epidermidis 510 8 8 4 8 16 64 8 8 0.5
S. epidermidis 511 8 8 4 4 32 64 8 8 32
S. epidermidis 515 4 8 8 4 32 64 8 8 32
S. epidermidis 431 8 8 4 8 16 64 8 8 8
S. epidermidis 432 8 8 4 8 32 64 8 8 64
S. epidermidis 433 4 8 4 4 32 64 8 4 64
S. epidermidis 435 8 8 4 8 32 128 8 8 0.25
S. epidermidis 436 8 8 4 8 32 128 8 8 ≤ 0.125
S. epidermidis 437 8 8 8 8 32 128 8 8 0.5
S. epidermidis 438 8 8 4 8 32 128 8 8 ≤ 0.125
S. epidermidis 513 8 8 4 8 16 64 8 8 0.5
Ref. *—Ciprofloxacin.
Most of the clinical strains of S. epidermidis were less susceptible to the presence
of the synthesized complexes. However, derivatives 1, 2, 4, 7 and 8 appeared to be
2–16 times more effective against S. epidermidis 424, 471, 511, 515 and 431–433 isolates
than the reference chemotherapeutic. Similarly, weak antimicrobials, such as disubstituted
compounds 5 and 6, were still equally or more potent towards these cocci, as compared
to ciprofloxacin.
To sum up, thiourea complexes incorporating a copper (II) ion expressed higher
inhibitory growth properties against hospital than standard bacterial rods. What is more,
their efficiency depended on the type of electronegative functionalities attached to the
benzene ring. Derivatives incorporating 3-chloro-4-fluorophenyl- (4) and 4-iodophenyl
substituents (8) showed the strongest effect towards both types of strains, while their
4-bromosubstituted analog (3) was powerful distinctly against clinical isolates. Ortho-substituted
compounds, bearing bromine (1) or fluorine (7) atoms, shared a similar inhibitory activity
when incubated with Staphylococci, but were weaker than the mentioned para-substituted.
Comparing dihalogeno derivatives 4 and 5, the replacement of the fluorine atom by chlorine
led to a severalfold decrease of the antimicrobial potency. On the other hand, the compound
possessing both chlorine and nitro group (6) was much more active against standard than
hospital S. aureus species.
As proved by Bacillus subtilis rec-assay test, newly synthesized complexes 1–8 exerted
no mutagenic and carcinogenic activities (Table S2). Thus, their antimicrobial effects were
not linked with DNA-damaging potency.
As compared to results obtained for complexes, the antimicrobial activities of parental
ligands were considerably higher [37]. MIC values of the most active ligands L1–L5, L7
and L8 against standard Staphylococcal strains ranged from 0.5 to 2 µg/mL. As expected,
new copper (II) complexes were much more potent than copper (II) chloride itself
(MIC ≥ 128 µg/mL for all strains). Although the complexation of halogen-containing
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4-chloro-3-nitrophenylthioureas with copper (II) ion diminished their antibacterial proper-
ties [36,37], it incomparably increased their cytotoxicity towards various cancer cell lines,
without influencing on normal keratinocytes.
Antimicrobial activity of the close analogs of the title complexes was previously
described [6,7]. The formerly tested copper (II) complex of 1-(3-chloro-4-fluorophenyl)-
3-[3-trifluoromethyl)phenylthiourea, an analog of the complex 4 described in this pa-
per, exerted comparable growth-inhibitory activity towards standard bacterial strains
(MIC 4–256 µg/mL) [7]. The same level of activities of both compounds was observed for
clinical strains (MIC 4–8 µg/mL). However, for the derivative of 3,4-dichlorophenylthiourea,
the observed differences in bioactivity were considerable. The complex of 3-(trifluoromethyl)
phenylthiourea inhibited the growth of Staphylococcal strains at 2 µg, whereas the coordi-
nate of 1-(4-chloro-3-nitrophenyl)-3-(3,4-dichlorophenyl)thiourea (5) was only at 32 µg/mL.
Variabilities in antibacterial actions were even higher when hospital strains were consid-
ered. The 3-(trifluoromethyl)phenylthiourea analog was 16-64 times more potent than its
4-chloro-3-nitrophenylthiourea counterpart (5). On the other hand, copper (II) complexes
with 2-bromo- and 3-bromophenylthiourea derivatives of 4-azatricyclo[5.2.1.0 2,6]dec-8-
ene-3,5-dione were poorly active in comparison with the 4-chloro-3-nitrophenyl thioureas
published in this paper [6]. The only exception was the 4-bromophenylthiourea with an
azatricyclodione terminal fragment, which was four times more active against standard
Staphylococcal isolates than its 3-chloro-4-fluorophenylthiourea analog (3). To conclude,
derivatives of substituted phenylthioureas, mainly 3-trifluoromethylphenylthiourea com-
plexes, revealed higher antimicrobial activity in comparison with coordinates of cyclic imides.
3. Materials and Methods
3.1. General Procedure
All chemicals were of analytical grade and were purchased from Sigma-Aldrich.
The melting point (m.p.) was determined on a Boetius (HMK65/ 1360) microscope.
Elemental analysis of all complexes was carried out using elemental analyzer CHNS
(Vario Micro Cube) with an electronic microbalance. The copper content for complex 5
was determined using the energy dispersive X-ray fluorescence spectrometer EDX-7000
from Shimadzu.
3.1.1. Synthesis of Cu (II) Complexes of 3-(4-Chloro-3-nitrophenyl)thiourea (1-8)
The appropriate 3-(4-chloro-3-nitrophenyl)thiourea L1–L8 (1 mmol) was stirred in
dimethylformamide (DMF) (2 mL) until its dissolution. Next, anhydrous copper (II)
chloride (1 mmol) was added to the solution. After stirring for 6 h, the solvent was
evaporated. The solid residue was collected, washed several times with cold distilled
water and dried in vacuo over anhydrous calcium chloride at room temperature to yield
complexes 1–8.
1. Copper (II) complex with 1-(2-bromophenyl)-3-(4-chloro-3-nitrophenyl)thiourea.
Yield 53%; dark brown solid; m.p. 93–95 ◦C; Anal. Calc for Cu(L1)2·0.75DMF·0.5 H2O;
Calc. C 37.76, H 2.50, N 10.52, Found C 37.92, H 2.28, N 10.57 (%).
2. Copper (II) complex with 1-(3-bromophenyl)-3-(4-chloro-3-nitrophenyl)thiourea.
Yield 61%; dark brown solid; m.p. 80–82 ◦C; Anal. Calc for Cu(L2)2·0.25 DMF·1.25 H2O,
Calc. C 36.69, H 2.23, N 10.00, Found C 36.28, H 2.39, N 10.40 (%).
3. Copper (II) complex with 1-(4-bromophenyl)-3-(4-chloro-3-nitrophenyl)thiourea.
Yield 58%; dark brown solid; m.p. 88–90 ◦C; Anal. Calc for Cu(L3)2·0.75 DMF·0.5 H2O,
Calc. C 37.76, H 2.50, N 10.52, Found C 38.04, H 2.24, N 10.30 (%).
4. Copper (II) complex with 1-(3-chloro-4-fluorophenyl)-3-(4-chloro-3-nitrophenyl)thiourea.
Yield 55%; dark brown solid; m.p. 95–97 ◦C; Anal. Calc for Cu(L4)2·0.75 DMF·0.5 H2O,
Calc. C 40.12, H 2.41, N 11.18, Found C 40.26, H 2.18, N 11.30 (%).
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5. Copper (II) complex with 1-(4-chloro-3-nitrophenyl)-3-(3,4-dichlorophenyl)thiourea.
Yield 57%; brown solid; m.p. 76–78 ◦C; Anal. Calc for Cu(L5)2·3.25H2O, Calc. C 35.76,
H 2.37, N 9.62, Cu 7.28, Found C 35.76, H 2.20, N 9.88, Cu 7.74 (%).
6. Copper (II) complex with 1,3-bis(4-chloro-3-nitrophenyl)thiourea.
Yield 45%; light yellow solid; m.p. 107–108 ◦C; Anal. Calc for Cu(L6)2 ·0.75 DMF·0.75 H2O,
Calc. C 37.52, H 2.31, N 13.55, Found C 37.41, H 2.22, N 13.41 (%).
7. Copper (II) complex with 1-(2-fluorophenyl)-3-(4-chloro-3-nitrophenyl)thiourea.
Yield 57%; yellow-green solid; m.p. 97–99 ◦C; Anal. Calc for Cu(L7)2·0.5 DMF·0.25 H2O,
Calc. C 43.8, H 2.67, N 12.07, Found C 43.82, H 2.47, N 12.22 (%).
8. Copper (II) complex with 1-(4-iodophenyl)-3-(4-chloro-3-nitrophenyl)thiourea.
Yield 47%; orange brown solid; m.p. 99–101 ◦C; Anal. Calc for Cu(L8)2 ·3.5 H2O, Calc.
C 31.48, H 2.32, N 8.47, Found C 31.20, H 2.08, N 8.50 (%).
3.1.2. Instrumentation
Infrared spectra were performed on Nicolet iS5 FTIR spectrometer (Thermo Scientific)
with diamond ATR sample accessory. The complexes 1–8 as well as organic ligands L1–L8
were recorded in the range of 400–4000 cm−1. The solid state electronic reflectance spec-
tra of complexes 1–8 were collected on SHIMADZU UV-2600 spectrophotometer with
UV-2600Plus Integrating Sphere in the range of 220–1400 nm. Electron paramagnetic res-
onance (EPR) spectra were recorded with a Bruker ELEXSYS-E580 X-band spectrometer
(100 kHz field modulation). The microwave power of 5 mW and the modulation amplitude
of 0.1–0.5 mT were applied. Prior, the measurements of the samples were dissolved in
a mixture of ethanol–toluene solvent (1:1 v/v) to form solution of ca. 0.1 mM. The EPR
measurements of frozen solutions were carried out at 77 K. The EPR parameters of the
copper complexes were determined by computer simulation of the experimental spectra
using the EPRsim32 package [60].
3.2. Cell Culture
The human primary (SW480), metastatic (SW620) colon cancer, metastatic prostate
cancer (PC3) and human immortal keratinocyte (HaCaT) cell lines were purchased from
the American Type Culture Collection (ATCC, Rockville, USA). The cells were cultured
in medium according to protocols (MEM for SW480 and SW620, RPMI 1640 for PC3 and
DMEM for HaCaT cells) supplemented with 10% fetal bovine serum (FBS), penicillin
(100 U/mL) and streptomycin (100 µg/mL) and cultured in 37 ◦C/ 5% CO2 humidified
incubator. The cells were cultured until appropriate confluence was achieved (80–90%).
Next, they were harvested by treatment with 0.25% trypsin (Gibco Life Technologies, USA)
and used for studies.
3.3. MTT Assay
To determine IC50 of the thiourea complexes, cells were seeded in 96-well plates
(1 × 104 cells per well) and treated for 72 h with different concentrations of compounds.
Cells without studied compounds in medium were used as a control.
The cell viability was assessed by determination of MTT salt (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) conversion by mitochondrial dehydrogenase. MTT assay
was performed as previously described [61]. Experiments were repeated three times.
Cell viability was presented as a percentage of MTT reduction in the treated cells versus
the control cells. Number of viable cells cultured without studied compounds was as-
sumed to be 100%. Decreased relative MTT level means decreased cell viability. Thiourea
complexes with the highest cytotoxic potential assessed by MTT determination (with the
lowest IC50) were chosen for subsequent assessments of cytotoxicity mechanisms.
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3.4. LDH Assay
The presence of lactate dehydrogenase (LDH) in culture medium indicates a distur-
bance of the integrity of the cellular membrane. The LDH activity was performed after
72 h incubation of cells (1 × 104 cells per well) in 96-well plates with selected compounds
according to manufacturer’s protocol (Roche Diagnostics, Germany), as was described by
Chrzanowska et al. [61]. Compound mediated cytotoxicity was determined using equation:
((A test sample−A low control)/ (A high control−A low control)) × 100% (A-absorbance),
where “low control” means cells in medium with 2% FBS without tested compounds,
and “high control” means cells incubated in medium with 2% FBS and 1% Triton X-100
(100% LDH release). The cytotoxicity was expressed as percentage of LDH release as
compared with the maximum release of LDH from Triton-X-100-treated cells.
3.5. Annexin V Binding Assay
The cells were cultured and harvested under the conditions described in the cell
culture section. Then, they were seeded in six-well plates (2 × 105 cells per well) and
treated with selected thioureas complexes at their IC50 concentration for 72 h. The effect of
these compounds on the process of early and late apoptosis and necrosis was determined,
as described previously [61], by dual staining with annexin V-FITC and propidium iodide
according to manufacturer’s protocol (Becton Dickinson). The cells that were annexin
V-FITC positive and PI-negative were identified as early apoptotic and annexin V-FITC
and PI-positive as late apoptotic or necrotic.
3.6. Il-6 Level Assay
IL-6 concentration at all studied cancer cells and normal HaCaT cell lines was mea-
sured by ELISA kit (Diaclon SAS Besancon Cedex, France). Cells were seeded in twelve-
well plates (1 × 105 cells per well) and treated with IC50 concentration of selected studied
complexes for 72 h. IL-6 in cell culture supernatant was measured using enzyme-linked
immunosorbent assay in accordance with the manufacturer’s protocol.
3.7. LC-MS Proteome Analysis
Enzymes involved in oxidoreductive potential were analyzed in the cell lysates ob-
tained after treatment cells with selected conjugates for 24 h. Cells were washed with
phosphate-buffered saline (PBS) and harvested, then centrifuged at 1000× g for 10 min.
Then, lysis buffer (containing protease inhibitor, 1% RIPA Lysis and Extraction Buffer
(ThermoFisher)) and cold PBS were added, and samples were sonicated three times in
ice bath. Next, the cell lysates were centrifuged at 14,000× g at 4 ◦C for 15 min, and then
supernatants were stored at 70 ◦C before use. Protein concentration was measured by the
Bradford method.
Normalized protein concentrations (5 µg) from cell lysate were precipitated by ice cold
(–20 ◦C) acetonitrile (ACN, Merck, in ratio 1:4). Then, samples were centrifuged (–9 ◦C,
30 min., 18,000× g), the supernatant was discarded and ACN excess was evaporated using
a vacuum centrifuge (5 min., room temp.). Protein pellet was dissolved in 40 mM ammo-
nium bicarbonate. An amount of 500 mM dithiothreitol (DTT, with final concentration
20 mM) and 1 M iodoacetamide (IAA, with final concentration 40 mM) were used for
reduction and alkylation processes. After 16 h of incubation in 37 ◦C with Trypsin Gold
(Promega), digested protein samples were diluted with 0.1% formic acid (ThermoFisher)
and centrifuged (+2 ◦C, 30 min, 18,000× g).
LC–MS analysis was carried out with the use of nanoUHPLC (nanoElute, Bruker)
coupled by CaptiveSpray (Bruker) to ESI-Q-TOF mass spectrometer (Compact, Bruker).
Two-column separation method was used, i.e., pre-column (300 µm× 5 mm, C18 PepMap 100,
5 µm, 100Å, Thermo Scientific) and Aurora separation column with CSI fitting (75 µm× 250 mm,
C18 1.6 µm) in gradient 2% B to 35% B in 90 min with the 300 nL/min flow rate. Mobile
phases (A) 0.1% formic acid in water and (B) 0.1% formic acid in ACN were used.
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Sample ionizations were performed at a gas flow of 3.0 L/min, temperature of 150 ◦C
and voltage of the capillary at 1600 V. The quadrupole energy was fixed to 5.0 eV and
collision chamber energy 7.0 eV, with an ion transfer time of 90 µs. The ions were analyzed
in the positive polarity mode in the range 150–2200 m/z, with the acquisition frequency of
the 1 Hz spectrum, as well as with the autoMS/MS system.
The collected spectra were analyzed and calibrated using DataAnalysis software
(Bruker) and then identified in ProteinScape (Bruker) by the MASCOT server. Protein
identification was conducted using the online SwissProt and NCBIprot databases, and
their references and biological significance were identified using Reactome.org, String.org
and KEGG.
3.8. In Vitro Evaluation of Antimicrobial Activity
The antimicrobial activity of the compounds was tested on Gram-positive bacteria
(Staphylococcus aureus NCTC 4163, Staphylococcus aureus ATCC 25923, Staphylococcus aureus
ATCC 6538, Staphylococcus aureus ATCC 29213, Staphylococcus epidermidis ATCC 12228,
Staphylococcus epidermidis ATCC 35984), Gram-negative rods (Escherichia coli ATCC 10538,
Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 15442, Pseudomonas aeruginosa
ATCC 27863) and yeasts (Candida albicans ATCC 10231, Candida albicans ATCC 90028,
Candida parapsilosis ATCC 22019). Hospital methicillin-resistant strains of Staphylococcus
aureus and Staphylococcus epidermidis were obtained from the collection of the Department
of Pharmaceutical Microbiology, Medical University of Warsaw, Poland.
Antibacterial activity was examined by the disc-diffusion method under standard
conditions using Mueller–Hinton II agar medium (Becton Dickinson) according to CLSI
(previously NCCLS) guidelines [62]. Antifungal activities were assessed using Mueller–
Hinton agar + 2% glucose and 0.5 µg/mL methylene blue dye medium [63]. Sterile filter
paper discs (9 mm diameter, Whatman Number 3 chromatography paper) were dripped
with tested compound solutions (in dimethylsulfoxide, DMSO) to load 400 µg of a given
compound per disc. Dry discs were placed on the surface of appropriate agar medium.
The results (diameter of the growth inhibition zone) were read after 18 h of incubation
at 35 ◦C. Minimal inhibitory concentration (MIC) was tested by the twofold serial mi-
crodilution method (in 96-well microtiter plates) using Mueller–Hinton broth medium
(Beckton Dickinson) for bacteria or RPMI-1640 medium for Candida species, according to
CLSI guidelines [64,65]. The stock solution of tested agent was prepared in DMSO and
diluted in sterile water. Concentrations of tested agents ranged from 0.125 to 512 µg/mL.
The final inoculum of all studied microorganisms was 105 CFU/ mL−1 (colony forming
units per ml). Minimal inhibitory concentrations (the lowest concentration of a tested agent
that prevents visible growth of a microorganism) were read after 18 h (bacteria) or 24 h
(yeasts) of incubation at 35 ◦C.
3.9. Genotoxicity Studies
DNA-damaging activity of compounds was tested by rec-assay using two genetically
modified Bacillus subtilis strains: M45 (rec−) and H17 (rec+) [66,67]. Tested compounds
were dissolved in DMSO, and 10 µL of each solution was dripped onto sterile cotton discs
(Rotilabo) to load 256 µg of a given compound per 9 mm disc. Discs were placed on the
surface nutrient agar plates (Difco), inoculated with 100 µL of bacterial overnight culture
and incubated 24 h at 35 ◦C. After incubation, the growth inhibition zones were measured.
4-nitroquinoline N-oxide (NOQ) was used as reference genotoxin (concentration 2 µg per
disc). Results of the genotoxicity test were estimated after 18 h of incubation at 35 ◦C by
comparing the diameter of the inhibition zone on the B. subtilis M45 (rec−) strain with that
on the B. subtilis H17 (rec+) strain.
3.10. Statistical Analyses
Statistical analyses were performed using GraphPad Prism 9 software (GraphPad
Software). Statistical significance was assessed by ANOVA with Dunnett’s post hoc test.
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p values below 0.05 were considered statistically significant. Data were presented as the
mean ± SD from at least three independent experiments.
4. Conclusions
To conclude, we have presented the cytotoxic influences of four-coordinate Cu (II)
complexes with 3-(4-chloro-3-nitrophenyl)thiourea derivatives on a panel of human can-
cer and normal cell lines, as well as on bacterial isolates. In contrast to initial ligands,
the complexation with metal ions has revealed the cytotoxic profile of synthesized com-
pounds towards tumor cells and to a lesser extent to bacterial strains. Diversity of a type,
a position and quantity of halogen substituents on the phenyl ring of the thiourea branch
allowed for the examination of the impact of the structure of synthesized complexes on
their bioactivity. Studied coordination compounds did not express cytotoxic effects in
normal cells (HaCaT) at clinically achievable concentrations, and they were also proven to
be non-genotoxic. The most active halogen phenylthiourea complexes (1, 3, 7, 8) showed
stronger anticancer potential against PC3 compared to colon cancer cell lines. They were
also more effective than the tested disubstituted derivatives (4–6). Compound 8 achieved
the highest percentage of LDH release from PC3 and SW480 cells. Studied complexes,
especially 3 and 8, induced early apoptosis in the above-mentioned pathological cells.
Additionally, all coordination compounds, with emphasis on derivatives 1 and 8, reduced
the secretion of IL-6 by tumor cell lines. Their interleukin-inhibitory properties in the se-
lected cells were equally as strong as doxorubicin. Moreover, new compounds were active
against selected strains of Staphylococci of clinical importance, being up to 2–64 times more
potent in comparison to the reference antibiotic, ciprofloxacin. Our preliminary studies
also showed the general tendency of tested compounds to disturb the antioxidant and
detoxifying systems in cancer cells, especially evident for complexes 3, 7 and 8. This is an
initial signal that this may be one of the cytotoxicity mechanisms. Such a diminishing effect
of compounds on the antioxidant defense of cancer cells may support the action of other
pro-oxidative agents, including drug resistance as well as support radiotherapy treatment.
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